Pancreatectomy for pancreatic cancer with reference to combined resection of the vessels, twenty nine year experience by a single surgeon

Keio Journal of Medicine

Volumn 58, Issue 2, 2009, Pages 103-109

  Sugiura, Yoshiaki ^a   Horio, Takuya ^b   Aiko, Satoshi ^b   Ishizuka, Takamitu ^b   Kumano, Isao ^b   Kato, Yutaro ^a   Kato, Ayu ^a   Kitajima, Masaki ^a  

^a International University of Health and Welfare Mita Hospital   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Hepatic artery; Pancreatectomy; Pancreatic cancer; Portal vein

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; GEMCITABINE;

ADULT; AGED; ARTERY SURGERY; ARTICLE; CANCER SURVIVAL; CELIAC ARTERY; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HEPATIC ARTERY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PORTAL VEIN; SUPERIOR MESENTERIC ARTERY; SURGEON; SURVIVAL RATE; VASCULAR SURGERY; VEIN SURGERY;

ADULT; AGED; FEMALE; HEPATIC ARTERY; HUMANS; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; PORTAL VEIN; SURVIVAL RATE;

EID: 68049147062     PISSN: 00229717     EISSN: 18801293     Source Type: Journal    
DOI: 10.2302/kjm.58.103     Document Type: Article

References (19)

1. Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Cambell KA, Sauter PK, Coleman J, Abrams RA, Hruban RH: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampulary adenocarcinoma, part 2: Randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002, 236: 355-366 (Pubitemid 34971345)
2. Japan Pancreas Society: General Rules for the Study of Pancreatic Cancer. 4th ed. 1993
3. Aapro MS, Martin C, Hatty S: Gemcitabine-a safety review. Anticancer Drugs 1998; 9: 191-201
4. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM Tarassoff P, Nelson R, Dorr FA, Stephens CD, VonHoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413
5. Maeyama R, Fukuyama T, Morimatsu K, Tamura T, Ishikawa N, Hachiya Y, Sako T, Hirano Y: A long-term survivor case with good quality of life due to biliary bypass and Gemcitabine for advanced pancreatic cancer. Jpn J Cancer Chemother 2007; 34: 1873-1875 (English Abstract)
6. Yamaguchi T, Nakamura K, Hara T, Sudou K, Denda T: Usefulness of TS-1+Gemcitabine Therapy for Advanced Pancreatic Cancer. Tan to Sui 2007; 28: 361-365 (Japanese)
7. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. British Journal of Cancer 2006, 94: 1575-1579 (Pubitemid 43924916)
8. Abrams RA, Grochow LB: Adjuvant therapy with chemotherapy and radiation therapy in the management of carcinoma of the pancreatic head. Surg Clin North Am 1995; 75: 925-938
9. Nagakawa T, Kurachi M, Konishi K, Miyazaki I: Translateral retroperitoneal approach for pancreatic carcinoma. Jpn J Surg 1982; 12: 229-233
10. Yeo CJ, Cameron JL, Sohn TA, Coleman J, Sauter PK, Hruban RH Pitt HA, Lillemoe DK: Pancreatoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampulary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg 1999; 229: 613-622 (Pubitemid 30187568)
11. Sugiura Y, Yoshizumi Y, Ono K, Kubota M, Aiko S, Kimura T, Segawa D, Hatori N, Yoshizu H, Tanaka S: Surgery for pancreas cancer with resection of the portal vein, hepatic artery and superior mesenteric artery. Jpn J Vasc Surg 1997; 6: 423-429 (English abstract)
12. Imaizumi T, Tobita K, Dowaki S, Ishii M, Makuuchi H: Radical resection with portal and/or arterial resection for the pancreatic cancer. Shokakigeka 2005; 28: 189-199 (Japanese)
13. Fujioka S, Misawa T, Okamoto T, Gocho T, Futagawa Y, Ishida Y, Yanaga K: Preoperative serum carcinoembryonic antigen and carbohydrate antigen levels for evaluation of curability and respectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg 2007; 14: 539-544 (Pubitemid 350201463)
14. Yeo Cj, Sohn TA, Cameron JL, Hruban RH Lillemoe KD, Pitt HA: Periampulary adenocarcinoma: analysis of 5-year survivors. Ann Surg 1999; 227: 736-737
15. Tani M, Kawai M, Terasawa H, Ina S, Hirono S, Shimamoto T, Miyazawa M, Uchiyama K, Yamaue H: Prognostic factors for long-term survival in patients with locally invasive pancreatic cancer. J Hepatobiliary Pancreat Surg 2007; 14: 545-550 (Pubitemid 350201464)
16. Kosuge T, Kiuchi T, Mukai K, Kakizoe T (the Japanese study group of adjuvant therapy for pancreatic cancer): A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 2006; 36: 159-165
17. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Kohler K, Bechstein W, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. A randomized controlled trial. JAMA 2007; 297: 267-277 (Pubitemid 46143304)
18. Ueda S, Ogata S, Tsuda H, Kawarabayashi N, Kimura M, Sugiura Y, Tamai S, Matsubara O, Hatsuse K, Mochizuki H: The correlation between cytoplasmic overexpression fo EGF receptor and tumor aggressiveness, poor prognosis in patients with pancreatic ductal carcinoma. Pancreas 2004; 29: 1-8
19. Einama T, Kagata Y, Tsuda H, Morita D, Ogata S, Ueda S, Takigawa T, Kawarabayashi N, Fukatsu K, Sugiura Y, Matsubara O, Hatsuse K: High-level Skp2 expression in pancreatic ductal adenocarcinoma: Correlation with extent of lymph node metastasis, higher histological grade, and poorer patient outcome. Pancreas 2006; 32: 376-381 (Pubitemid 43772193)